SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
PARSIPPANY, N.J., Jan. 03, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference at 3:30 p.m. PT (6:30 p.m. ET) on Monday, January 9, 2017, in San Francisco. Mr. Stack is expected to present an overview of the company.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), a non-opioid local analgesic for postsurgical pain control, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
